Comparative Study Between Serum Level of Lysophosphatidic Acid and CA-125 in Epithelial Ovarian Cancer

被引：1
作者：
Rady H.A. [1 ]
Othman M.M. [1 ]
Agamia A.F.M. [1 ]
Mahmoud M.H. [2 ]
Elghrabawy S.A. [1 ]
机构：
[1] Department of Obstetrics and Gynaecology, Faculty of Medicine, Alexandria University, Alexandria
[2] Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria
来源：
Indian Journal of Gynecologic Oncology | 2018年 / 16卷 / 3期
关键词：
Benign ovarian tumor; CA-125; Epithelial ovarian cancer; Lysophosphatidic acid;
D O I：
10.1007/s40944-018-0204-y
中图分类号：
学科分类号：
摘要：
Background: The aim of this study is to assess the diagnostic value of lysophosphatidic acid (LPA) in epithelial ovarian cancer (EOC) patients in comparison with CA125. Methods: The study included 41 women with EOC and 41 women with benign ovarian tumor. Serum CA-125 and LPA levels were measured and correlated with histopathological examination results. Results: Ovarian cancer patients have increased LPA and cancer antigen CA-125 levels compared to patients with benign ovarian tumor (LPA: ovarian cancer vs. benign ovarian tumor: 2.43 ± 1.69 vs. 0.6 ± 0.71 μmol/L; CA-125: ovarian cancer vs. benign ovarian tumor: 604.55 ± 865.84 vs. 86.71 ± 194.87 U/mL), which showed statistically significant differences (both P < 0.05). LPA with advanced sensitivity (92.68%), specificity (87.8%), positive predictive value (88.37%) and negative predictive value (92.31%) is compared with CA-125 in the diagnosis of ovarian cancer. The areas under the receiver operating characteristic curve are in the diagnosis of ovarian cancer (LPA: 0.925; CA-125: 0.779). Conclusion: LPA has greater value, and it is a better biomarker for diagnosis of EOC compared to CA-125. © 2018, Association of Gynecologic Oncologists of India.
引用
收藏
相关论文
共 17 条
  • [1] Reid B.M., Permuth J.B., Sellers T.A., Epidemiology of ovarian cancer: a review, Cancer Biol Med, 14, 1, pp. 9-32, (2017)
  • [2] Rauh-Hain J.A., Krivak T.C., Del Carmen M.G., Olawaiye A.B., Ovarian cancer screening and early detection in the general population, Rev Obstet Gynecol, 4, 1, pp. 15-21, (2011)
  • [3] Ibrahim A.S., Khaled H.M., Mikhail N.N., Baraka H., Kamel H., Cancer incidence in Egypt: results of the national population-based cancer registry program, J Cancer Epidemiol, 2014, pp. 1-18, (2014)
  • [4] Lengyel E., Ovarian cancer development and metastasis, Am J Pathol, 177, 3, pp. 1053-1064, (2010)
  • [5] Lu Z., Chen Y., Hu Z., Hu C., Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis, Int J Gynecol Cancer, 25, 1, pp. 18-23, (2015)
  • [6] Cooper C.P., Gelb C.A., Trivers K.F., Stewart S.L., Intended care seeking for ovarian cancer symptoms among U.S. women, Prev Med Rep, 3, pp. 234-237, (2016)
  • [7] Sedlakova I., Vavrova J., Tosner J., Hanousek L., Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer, Tumour Biol, 32, 2, pp. 311-316, (2011)
  • [8] Wei S.U., Li H., Zhang B., The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer, Biomed Rep, 5, 1, pp. 41-44, (2016)
  • [9] Lin F.T., Lin V.Y., Lin V.T., Lin W.C., TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation, Cell Discov, 2, (2016)
  • [10] Yu X., Zhang Y., Chen H., LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study, BMC Cancer, 16, 1, (2016)
12